EUVIMEDEUVIMED entdecken
Kommentar

Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded

David Saceda-Corralo iD, Sergio Vañó-Galván iD

British Journal of Dermatology · 17.07.2026 · 195 (2) · 200-201

DOI: 10.1093/bjd/ljag166 ↗

Kurz gefasst

Kommentar in der Zeitschrift British Journal of Dermatology, online erschienen am 05.05.2026. Verfasst von David Saceda-Corralo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, University Hospital Ramón y Cajal, Madrid, Spain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

David Saceda-Corralo, Sergio Vañó-Galván; TYK2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded, British Journal of Dermato

Autor:innen und Institutionen

  • Dermatology Department, University Hospital Ramón y Cajal, Madrid, Spain.
  • Hair Disorders Unit, Grupo Pedro Jaén, Madrid, Spain.

ORCID-Profile: David Saceda-Corralo, Sergio Vañó-Galván

Zitieren

APA

Saceda-Corralo, D., & Vañó-Galván, S. (2026). Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded. British Journal of Dermatology, 195(2), 200-201. https://doi.org/10.1093/bjd/ljag166

Vancouver

Saceda-Corralo D, Vañó-Galván S. Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded. British Journal of Dermatology. 2026;195(2):200-201. doi:10.1093/bjd/ljag166

BibTeX
@article{SacedaCorralo2026,
  author = {Saceda-Corralo, David and Vañó-Galván, Sergio},
  title = {Tyrosine kinase 2 inhibition in alopecia areata: why deucravacitinib failed where others succeeded},
  journal = {British Journal of Dermatology},
  year = {2026},
  volume = {195},
  number = {2},
  pages = {200--201},
  doi = {10.1093/bjd/ljag166}
}
Kostenlos starten →